NCT05838885已完成2 期
A Multicenter, Randomized, Open-label, Positive-controlled Phase 2 Study to Explore the Optimal Dose of Y- Shaped Pegylated Recombinant Growth Hormone (YPEG-rhGH) in Children With Short Stature (ISS, SGA, TS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 78
- 试验地点
- 19
- 主要终点
- Pharmacokinetic-terminal disposition phase half-life
研究概览
简要总结
To explore the dose-response relationship between pharmacokinetics and pharmacodynamics of Y- Shaped Pegylated growth hormone injection (YPEG-GH) in children with short stature (idiopathic short stature (ISS), small for gestational age (SGA), Turner syndrome (TS)).
To evaluate its tolerability, safety and efficacy and to provide evidence for dose selection and titration for future clinical development and clinical application in these population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prepubertal (Tanner I), aged older than 4 years and younger than10 years for girls and 11 years for boys.
- •Body weight: 12kg ≤ body weight ≤ 50kg.
- •For children with idiopathic short stature: a) Birth length and weight were at the 10th percentile and above of normal reference values for infants of the same gestational age and sex; b) Height at screening was 2.0 standard deviations (SD) below the mean height for chronological age and sex c) Exclude other causes such as systemic diseases, other endocrine diseases, nutritional diseases, chromosomal abnormalities, skeletal dysplasia, psycho-emotional disorders, etc. were excluded d) GH peak ≥10.0ng/ml confirmed by two different drug GH provocation tests; e) Bone age (BA)-chronological age (CA) ≤1 year.
- •For children with small for gestational age: a) Birth length and weight were at the 10th percentile and below the normal reference values for infants if the same gestational age and sex; b) Gestational age at birth ≥ 24 weeks; c) Height at screening was below -2 SD of the mean for the same age and sex, and please refer to the protocol annex 1 for height.
- •For children with Turner syndrome: a) Chromosome karyotype: 45, X; 45, X/46, XXqi; 45, X/46, XXr; 45, X/46, XX; 46, XXqi; 46, XXpi; 45, X/47, XXX; 46, XXp-; 45, X/46, XXp-; 46, XXq-; 45, x/46, XXq-; 45, X/46, XX/47, XXX, etc.; b) Having at least one specific physical characteristic: Including but not limited to low posterior hairline, facial skin nevus, neck flips, short neck, low ear position, small jaw, high palatal arch, shield chest, wide breast spacing, elbow ectropion, knee ectropion, short 4th and 5th metacarpal, nail dysplasia, scoliosis, ptosis, strabismus, cardiovascular system abnormalities such as aortic stenosis, bicuspid aortic valve, hypertension, and reproductive system abnormalities such as primary gonadal insufficiency, renal malformation, hypothyroidism and middle ear disease; c) The height at screening was below the mean -2SD of the same age and gender, and please refer to the protocol annex 1 for height.
- •Understands and signs the informed consent form voluntarily by the subject's parent(s) and/or legal guardian(s). And written assent of the subject is required if the subject is 8 years of age or older).
排除标准
- •For children with small for gestational: confirmed or suspected Bloom syndrome.
- •For children with Turner syndrome: containing a Y chromosome or a fragment derived from a Y chromosome.
- •Children with closed epiphysis.
- •Children who diagnosed or highly suspected growth hormone deficiency (GHD), or other types of growth abnormalities: e.g., Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, etc.
- •Children who have previously received systemic growth-promoting therapy, including but not limited to rhGH, aromatase inhibitors, sex hormones, etc., for at least 1 month or longer.
- •Children who are now receiving or plan to receive the therapy of glucocorticoids, methylphenidate, and any other drugs that may have an effect on growth.
- •Children with abnormal values of liver and kidney function (ALT > 1.5 ULN, Cr > 1 ULN).
- •Concomitant with chronic hepatitis B, AIDS, tuberculosis, and any other chronic infectious disease.
- •Patients with severe allergic constitutions or allergic to growth hormone or its excipients such as mannitol, lysine, sodium chloride and other ingredients.
- •Patients with a previous history of malignancy or are currently suffering from active malignancy, including intracranial tumors.
- •Patients with abnormal glucose regulation (including abnormal fasting glucose and/or abnormal glucose tolerance) or diabetes.
- •Patients who are mentally ill or have a family history of mental illness.
- •Patients who are suffering from chronic systemic diseases, such as malnutrition, immunocompromised individuals, asthma, etc.
- •Patients with congenital intracranial hypertension.
- •Patients with slipped capital femoral epiphysis (SCFE).
- •Patients with scoliosis exceeding 15°;
- •Patients who have participated in any drug clinical study (as a subject) within 3 months prior to screening and have received a drug intervention
- •Patients who the investigators considered unfit for the study.
研究组 & 干预措施
YPEG-GH low dose group
Experimental
干预措施: YPEG-rhGH (Drug)
YPEG-GH high dose group
Experimental
干预措施: YPEG-rhGH (Drug)
rhGH low dose group
Active Comparator
干预措施: rhGH (Drug)
rhGH high dose group
Active Comparator
干预措施: rhGH (Drug)
结局指标
主要结局
Pharmacokinetic-terminal disposition phase half-life
时间窗: up to 52 weeks
Pharmacokinetic-terminal elimination rate constant
时间窗: up to 52 weeks
Pharmacokinetic-apparent clearance after extravascular administration
时间窗: up to 52 weeks
Pharmacokinetic-area under plasma concentration versus time curve
时间窗: up to 52 weeks
Pharmacokinetic-maximum serum concentration
时间窗: up to 52weeks
Pharmacokinetic-apparent volume of distribution
时间窗: up to 52 weeks
Pharmacokinetic-time to reach the maximum plasma concentration
时间窗: up to 52 weeks
次要结局
- Adverse events (including injection site reactions), changes from baseline in vital signs and laboratory tests(up to 57 weeks)
- Height standard deviation according to chronological age (Ht SDS CA)(At 52 weeks of treatment)
- Height velocity (HV, cm/year)(At 52 weeks of treatment)
- Pharmacodynamics-the properties of Insulin-like growth facto1 and Insulin-like growth factor binding receptor 3.(up to 57 weeks)
- Change of height velocity compared to baseline (ΔHV, cm/year)(At 52 weeks of treatment)
- Change in bone age(At 52 weeks of treatment)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male VolunteersHealthyNCT01415466Daewoong Pharmaceutical Co. LTD.36
已完成
4 期
An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative PainPostoperative PainNCT00465647Purdue Pharma LP116
已完成
1 期
Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult VolunteersHealthyNCT02089399Daewoong Pharmaceutical Co. LTD.32
已完成
1 期
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic AlopeciaAndrogenic AlopeciaNCT02824380Dong-A ST Co., Ltd.14
已完成
1 期
Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy CaucasiansHealthyNCT05005065HK inno.N Corporation20